Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients

被引:0
|
作者
Horesh, Adi [1 ]
Pollack, Rena [1 ,2 ]
Nechushtan, Hovav [1 ,3 ]
Dresner-Pollak, Rivka [1 ,2 ]
Neuman, Tzahi [1 ,4 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hadassah Hebrew Univ, Med Ctr, Dept Endocrinol & Metab, Jerusalem, Israel
[3] Hadassah Hebrew Univ, Med Ctr, Dept Oncol, Jerusalem, Israel
[4] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel
关键词
PD-L1; NSCLC; immune checkpoint inhibitors; immune-related adverse events; thyroid; ADVERSE EVENTS; NIVOLUMAB; PEMBROLIZUMAB; ANTIBODIES; TSH; P53;
D O I
10.3389/pore.2023.1610951
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), however are frequently associated with thyroid immune-related adverse events (IRAEs). We investigated the association between patient characteristics, tumor PD-L1 expression and molecular profile with the development of thyroid IRAEs in NSCLC patients.Methods: Single center, retrospective study including 107 NSCLC patients treated with PD-1/PD-L1 inhibitors from April 2016 to July 2020. All patients were euthyroid at baseline with at least two TSH measurements post-treatment initiation. The primary outcome was the difference in tumor PD-L1 expression in patients who developed any thyroid IRAEs versus those who remained euthyroid. Additional outcomes included development of overt thyroid dysfunction, the association of specific molecular alterations with thyroid IRAEs, and onset of thyroid IRAEs as a function of tumor PD-L1 expression.Results: Overall, 37 (34.6%) patients developed any thyroid dysfunction and 18 (16.8%) developed overt thyroid dysfunction. Tumor PD-L1 staining intensity was not associated with thyroid IRAEs. TP53 mutation was less likely to be associated with any thyroid dysfunction (p < 0.05) and no association was found between EGFR, ROS, ALK or KRAS mutations. There was no association between PD-L1 expression and time to develop thyroid IRAEs.Conclusion: PD-L1 expression is not associated with the development of thyroid dysfunction in advanced NSCLC patients treated with ICIs, suggesting that thyroid IRAEs are unrelated to tumor PD-L1 expression.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth
    Rawangkan, Anchalee
    Wongsirisin, Pattama
    Namiki, Kozue
    Iida, Keisuke
    Kobayashi, Yasuhito
    Shimizu, Yoshihiko
    Fujiki, Hirota
    Suganuma, Masami
    MOLECULES, 2018, 23 (08)
  • [32] Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma
    Lara, Matthew S.
    Afify, Alaa
    Ellis, Michael P.
    Phan, Chinh T.
    Richman, David P.
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2019, 20 (04) : E489 - E491
  • [33] INTRATUMORAL EXPRESSION OF PD-1/PD-L1 IMMUNE CHECKPOINT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Baquerizo, Angeles
    Vavinskaya, Vera
    Rojas, Angela
    Mhoyan, Anna
    Romero-Gomez, Manuel
    Sher, Linda
    Madani, Bahar
    Fisher, Jonathan
    Schaffer, Randolph
    Frenette, Catherine T.
    Marsh, Christopher
    HEPATOLOGY, 2019, 70 : 206A - 206A
  • [34] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    MODERN PATHOLOGY, 2018, 31 : 755 - 755
  • [35] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [36] Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study
    Wei, Xiao-Chen
    Guo, Yuan-Yuan
    Zhang, Yi
    Bu, Yi-Shan
    Zhang, Feng-Ying
    JOURNAL OF CHEMOTHERAPY, 2024, 36 (08) : 654 - 661
  • [37] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [38] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [39] Longitudinal evaluation of PD-L1 expression on circulating tumor cells in advanced NSCLC patients treated with nivolumab
    Sato, Koichi
    Koh, Yasuhiro
    Ikeda, Mio
    Akamatsu, Hiroaki
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2021, 112 : 533 - 533
  • [40] A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
    Wang, Yuanyuan
    Gu, Tingxuan
    Tian, Xueli
    Li, Wenwen
    Zhao, Ran
    Yang, Wenqian
    Gao, Quanli
    Li, Tiepeng
    Shim, Jung-Hyun
    Zhang, Chengjuan
    Liu, Kangdong
    Lee, Mee-Hyun
    FRONTIERS IN IMMUNOLOGY, 2021, 12